Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

7,608 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Lower levels of insulin-like growth factor-1 standard deviation score are associated with histological severity of non-alcoholic fatty liver disease.
Sumida Y, Yonei Y, Tanaka S, Mori K, Kanemasa K, Imai S, Taketani H, Hara T, Seko Y, Ishiba H, Okajima A, Yamaguchi K, Moriguchi M, Mitsuyoshi H, Yasui K, Minami M, Itoh Y. Sumida Y, et al. Among authors: mori k. Hepatol Res. 2015 Jul;45(7):771-81. doi: 10.1111/hepr.12408. Epub 2014 Sep 30. Hepatol Res. 2015. PMID: 25163357
Development of hepatocellular carcinoma in Japanese patients with biopsy-proven non-alcoholic fatty liver disease: Association between PNPLA3 genotype and hepatocarcinogenesis/fibrosis progression.
Seko Y, Sumida Y, Tanaka S, Mori K, Taketani H, Ishiba H, Hara T, Okajima A, Umemura A, Nishikawa T, Yamaguchi K, Moriguchi M, Kanemasa K, Yasui K, Imai S, Shimada K, Itoh Y. Seko Y, et al. Among authors: mori k. Hepatol Res. 2017 Oct;47(11):1083-1092. doi: 10.1111/hepr.12840. Epub 2016 Dec 15. Hepatol Res. 2017. PMID: 27862719
Effect of 12-week dulaglutide therapy in Japanese patients with biopsy-proven non-alcoholic fatty liver disease and type 2 diabetes mellitus.
Seko Y, Sumida Y, Tanaka S, Mori K, Taketani H, Ishiba H, Hara T, Okajima A, Umemura A, Nishikawa T, Yamaguchi K, Moriguchi M, Kanemasa K, Yasui K, Imai S, Shimada K, Itoh Y. Seko Y, et al. Among authors: mori k. Hepatol Res. 2017 Oct;47(11):1206-1211. doi: 10.1111/hepr.12837. Epub 2016 Dec 5. Hepatol Res. 2017. PMID: 27917557
Effect of sodium glucose cotransporter 2 inhibitor on liver function tests in Japanese patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus.
Seko Y, Sumida Y, Tanaka S, Mori K, Taketani H, Ishiba H, Hara T, Okajima A, Umemura A, Nishikawa T, Yamaguchi K, Moriguchi M, Kanemasa K, Yasui K, Imai S, Shimada K, Itoh Y. Seko Y, et al. Among authors: mori k. Hepatol Res. 2017 Sep;47(10):1072-1078. doi: 10.1111/hepr.12834. Epub 2016 Dec 7. Hepatol Res. 2017. PMID: 27925353
Combination of PNPLA3 and TLL1 polymorphism can predict advanced fibrosis in Japanese patients with nonalcoholic fatty liver disease.
Seko Y, Yamaguchi K, Mizuno N, Okuda K, Takemura M, Taketani H, Hara T, Umemura A, Nishikawa T, Moriguchi M, Yasui K, Kamaguchi M, Nishioji K, Mochizuki N, Kobayashi M, Mori K, Tanaka S, Matsuura K, Tanaka Y, Itoh Y. Seko Y, et al. Among authors: mori k. J Gastroenterol. 2018 Mar;53(3):438-448. doi: 10.1007/s00535-017-1372-8. Epub 2017 Jul 25. J Gastroenterol. 2018. PMID: 28744823
Use of Mac-2 binding protein as a biomarker for nonalcoholic fatty liver disease diagnosis.
Kamada Y, Ono M, Hyogo H, Fujii H, Sumida Y, Yamada M, Mori K, Tanaka S, Maekawa T, Ebisutani Y, Yamamoto A, Takamatsu S, Yoneda M, Kawada N, Chayama K, Saibara T, Takehara T, Miyoshi E; Japan Study Group of Nonalcoholic Fatty Liver Disease (JSG‐NAFLD). Kamada Y, et al. Among authors: mori k. Hepatol Commun. 2017 Aug 16;1(8):780-791. doi: 10.1002/hep4.1080. eCollection 2017 Oct. Hepatol Commun. 2017. PMID: 29404494 Free PMC article.
7,608 results